DAAs with ribavirin yielded strong SVR rates in patients with HCV, HIV

July 21, 2014 8:50 PM

17 0

A regimen of three direct-acting-antiviral agents plus ribavirin was safe and effective among patients with hepatitis C virus infection and HIV, according to research presented at the International AIDS Conference in Melbourne, Australia.

In the TURQUOISE-I study, Mark Sulkowski, MD, Johns Hopkins University, and colleagues analyzed data from 63 patients (92.1% men), including 56 with hepatitis C virus (HCV) genotype 1 infection and HIV-1. They were treated with three direct-acting-antiviral agents (ABT-450 co-dosed with ritonavir, o...

Read more

To category page